Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.

Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, Paredes R, Olvera A, Haro I, Brander C, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V.

PLoS One. 2018 Dec 19;13(12):e0208345. doi: 10.1371/journal.pone.0208345. eCollection 2018.

2.

Lipid raft-like liposomes used for targeted delivery of a chimeric entry-inhibitor peptide with anti-HIV-1 activity.

Gómara MJ, Pérez-Pomeda I, Gatell JM, Sánchez-Merino V, Yuste E, Haro I.

Nanomedicine. 2017 Feb;13(2):601-609. doi: 10.1016/j.nano.2016.08.023. Epub 2016 Aug 24.

PMID:
27565689
3.

Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.

Sanchez-Merino V, Fabra-Garcia A, Gonzalez N, Nicolas D, Merino-Mansilla A, Manzardo C, Ambrosioni J, Schultz A, Meyerhans A, Mascola JR, Gatell JM, Alcami J, Miro JM, Yuste E.

J Virol. 2016 May 12;90(11):5231-5245. doi: 10.1128/JVI.00049-16. Print 2016 Jun 1.

4.

Antibody-Based Preventive and Therapeutic Strategies Against HIV.

Fabra-Garcia A, Beltran C, Sanchez-Merino V, Yuste E.

Curr HIV Res. 2016;14(3):260-9. Review.

PMID:
26957200
5.

Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.

Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.

Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. doi: 10.1016/j.bbagen.2016.02.008. Epub 2016 Feb 22.

PMID:
26905802
6.

HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity.

Pernas M, Sanchez-Merino V, Casado C, Merino-Mansilla A, Olivares I, Yuste E, Lopez-Galindez C.

PLoS One. 2015 Aug 10;10(8):e0134054. doi: 10.1371/journal.pone.0134054. eCollection 2015.

7.

HIV-1 inhibiting capacity of novel forms of presentation of GB virus C peptide domains is enhanced by coordination to gold compounds.

Gómara MJ, Galatola R, Gutiérrez A, Gimeno MC, Gatell JM, Sánchez-Merino V, Yuste E, Haro I.

Curr Med Chem. 2014;21(2):238-50. Review.

PMID:
24083612
8.

Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.

Ferreira CB, Merino-Mansilla A, Llano A, Pérez I, Crespo I, Llinas L, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V.

J Virol. 2013 Nov;87(22):12227-36. doi: 10.1128/JVI.02155-13. Epub 2013 Sep 4.

9.

Influenza, but not HIV-specific CTL epitopes, elicits delayed-type hypersensitivity (DTH) reactions in HIV-infected patients.

Ruiz-Riol M, Mothe B, Gandhi RT, Bhardwaj N, Scadden DT, Sanchez-Merino V, Brander C.

Eur J Immunol. 2013 Jun;43(6):1545-54. doi: 10.1002/eji.201242732. Epub 2013 Apr 17.

10.

Low-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfected HIV-1 LTNP elite controller.

Pernas M, Casado C, Arcones C, Llano A, Sánchez-Merino V, Mothe B, Vicario JL, Grau E, Ruiz L, Sánchez J, Telenti A, Yuste E, Brander C, Galíndez CL.

PLoS One. 2012;7(2):e31928. doi: 10.1371/journal.pone.0031928. Epub 2012 Feb 24.

11.

Definition of the viral targets of protective HIV-1-specific T cell responses.

Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, Zamarreño J, Bach V, Zuniga R, Pérez-Álvarez S, Berger CT, Puertas MC, Martinez-Picado J, Rolland M, Farfan M, Szinger JJ, Hildebrand WH, Yang OO, Sanchez-Merino V, Brumme CJ, Brumme ZL, Heckerman D, Allen TM, Mullins JI, Gómez G, Goulder PJ, Walker BD, Gatell JM, Clotet B, Korber BT, Sanchez J, Brander C.

J Transl Med. 2011 Dec 7;9:208. doi: 10.1186/1479-5876-9-208.

12.

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.

Medina-Ramírez M, Sánchez-Merino V, Sánchez-Palomino S, Merino-Mansilla A, Ferreira CB, Pérez I, González N, Alvarez A, Alcocer-González JM, García F, Gatell JM, Alcamí J, Yuste E.

J Virol. 2011 Jun;85(12):5804-13. doi: 10.1128/JVI.02482-10. Epub 2011 Apr 6.

13.

Human immunodeficiency virus type 1 and related primate lentiviruses engage clathrin through Gag-Pol or Gag.

Popov S, Strack B, Sanchez-Merino V, Popova E, Rosin H, Göttlinger HG.

J Virol. 2011 Apr;85(8):3792-801. doi: 10.1128/JVI.02329-10. Epub 2011 Feb 2.

14.

Programmed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usage.

Greenough TC, Campellone SC, Brody R, Jain S, Sanchez-Merino V, Somasundaran M, Luzuriaga K.

PLoS One. 2010 Sep 23;5(9):e12926. doi: 10.1371/journal.pone.0012926.

15.

Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy.

Shiu C, Cunningham CK, Greenough T, Muresan P, Sanchez-Merino V, Carey V, Jackson JB, Ziemniak C, Fox L, Belzer M, Ray SC, Luzuriaga K, Persaud D; Pediatric AIDS Clinical Trials Group P1059 Team.

J Virol. 2009 Oct;83(19):9731-42. doi: 10.1128/JVI.00570-09. Epub 2009 Jul 15.

16.

Identification and characterization of HIV-1 CD8+ T cell escape variants with impaired fitness.

Sanchez-Merino V, Farrow MA, Brewster F, Somasundaran M, Luzuriaga K.

J Infect Dis. 2008 Jan 15;197(2):300-8. doi: 10.1086/524845.

PMID:
18177249
17.

Genetic changes associated with distinct patterns of HIV type 1 persistence in chronically infected cell lines.

Sanchez-Merino V, Muñoz L, Pérez-Pastrana ME, Herrera MI, Olivares I, Lopez-Galindez C.

AIDS Res Hum Retroviruses. 2007 Feb;23(2):251-60.

PMID:
17331031
18.

HIV-1-specific CD8+ T cell responses and viral evolution in women and infants.

Sanchez-Merino V, Nie S, Luzuriaga K.

J Immunol. 2005 Nov 15;175(10):6976-86.

19.

Genetic analysis of culture-negative UNAIDS subtype C samples.

Sánchez-Merino V, Herrero CC, Amorin-Nink A, von Briesen H, López-Galíndez C; World Health Organization-UNAIDS Network for Isolation and Characterization.

AIDS Res Hum Retroviruses. 2003 Jan 1;19(1):49-55.

PMID:
12596720
20.

Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.

Peters S, Muñoz M, Yerly S, Sanchez-Merino V, Lopez-Galindez C, Perrin L, Larder B, Cmarko D, Fakan S, Meylan P, Telenti A.

J Virol. 2001 Oct;75(20):9644-53.

21.

Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity.

Olivares I, Sánchez-Merino V, Martínez MA, Domingo E, López-Galíndez C, Menéndez-Arias L.

J Virol. 1999 Aug;73(8):6293-8.

Supplemental Content

Loading ...
Support Center